Oncternal Therapeutics

152 articles about Oncternal Therapeutics

• Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

  4/18/2024

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI).

• Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

  3/15/2024

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer.

• Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

  3/7/2024

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.

• Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

  2/29/2024

  Oncternal Therapeutics, Inc. announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024.

• Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

  2/6/2024

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

• Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 1, 2024

  2/1/2024

  Oncternal Therapeutics, Inc. today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science.

• Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

  1/8/2024

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI).

• Oncternal Therapeutics Announces Reverse Stock Split - Jan 04, 2024

  1/4/2024

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that its board of directors has approved a 1-for-20 reverse stock split of the company's common stock.

• Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024

  1/2/2024

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager.

• Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

  12/26/2023

  Oncternal Therapeutics, Inc. updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment.

• Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

  11/9/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.

• Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

  11/2/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023.

• Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  10/26/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer (mCRPC) resistant to approved androgen receptor pathway inhibitors (ARPIs).

• Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

  10/25/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

• Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

  10/5/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.

• Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

  9/7/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB).

• Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

  8/10/2023

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported second quarter 2023 financial results.

• Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

  8/3/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets close on Thursday, August 10, 2023.

• Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

  8/3/2023

  Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs).

• Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2023

  6/30/2023

  Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.